Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19
The University of Tokyo · National Center for Global Health and Medicine · +6 more institutions
Indexed incrossrefdoajpubmed
Abstract
Importance
Treatment options for COVID-19 are warranted irrespective of the presence of risk factors for severe disease.
Objective
To assess the efficacy and safety of ensitrelvir in patients with mild to moderate COVID-19. Design, Setting, and Participants: This phase 3 part of a phase 2/3, double-blind, placebo-controlled randomized clinical trial was conducted from February 10 to July 10, 2022, with a 28-day follow-up period, at 92 institutions in Japan, Vietnam, and South Korea. Patients (aged 12 to
Citation impact
112
total citations
- FWCI
- 38.96
- Percentile
- 100%
- References
- 33
Citations per year
Authors
13Topics & keywords
Topics
Keywords
- Medicine
- Placebo
- Randomized controlled trial
- Clinical endpoint
- Internal medicine
- Population
- Coronavirus disease 2019 (COVID-19)
- Pediatrics
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.